National Health Investors (NHI) is in focus after management announced a dividend increase and raised full-year guidance. Investors are watching closely ahead of the Q3 2025 earnings report.

See our latest analysis for National Health Investors.

The share price for National Health Investors has seen notable swings in recent months, gaining over 10% year-to-date and delivering a 4.4% total shareholder return over the last year. Positive momentum from the dividend boost and updated guidance has kept investor sentiment leaning optimistic. Substantial long-term gains of nearly 80% total return over five years reflect its resilience and income appeal.

If moves like NHI’s dividend lift have you rethinking your portfolio mix, this could be an ideal moment to discover fast growing stocks with high insider ownership.

With shares trading near recent highs and analyst price targets now trailing the current price, investors face a key question: is National Health Investors undervalued with more upside to come, or is all future growth already priced in?

With National Health Investors closing at $75.33 and the narrative fair value at $83.14, the story suggests a meaningful gap between price and potential. The current setup has investors wondering what could unlock the next leg higher.

NHI's focused expansion of its SHOP (Senior Housing Operating Portfolio) segment, with double-digit NOI growth projected and a robust pipeline of accretive acquisitions, positions the company for outsized multi-year NOI and earnings growth relative to peers.

Read the complete narrative.

Want to crack the code behind this valuation? One key driver is that the narrative builds in strong future profit margins and ambitious growth projections that most companies can only dream of. Could these financial assumptions really justify a higher share price? Dive in to reveal the full rationale and decide if the crowd has it right.

Result: Fair Value of $83.14 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, near-term softness in occupancy and reliance on share issuances for funding could present challenges to the optimistic case for sustained margin and earnings growth.

Find out about the key risks to this National Health Investors narrative.

While valuation using market multiples offers one perspective, the SWS DCF model signals something more dramatic for National Health Investors. Our DCF calculations reveal the stock trading at a striking 50% discount to fair value. This suggests there may be far greater upside than the market-based approaches currently indicate. Could the real opportunity be hiding in plain sight?

Look into how the SWS DCF model arrives at its fair value.

If you have your own perspective or enjoy hands-on research, you can easily build your own story using the data in just a few minutes. Do it your way.

A great starting point for your National Health Investors research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.

Get ahead of the curve and sharpen your portfolio by targeting opportunities others might miss. The right screener can reveal promising stocks that fit your strategy. Do not let these insights pass you by!

Capitalize on undervalued gems by checking out these 868 undervalued stocks based on cash flows for companies trading below their intrinsic worth, flagged by robust cash flow analysis.

Accelerate your growth returns with these 27 AI penny stocks featuring companies at the forefront of artificial intelligence innovation and disruption.

Start earning steady income by exploring 3%;elm:context_link;itc:0;sec:content-canvas\\" class=\\"link \\">these 17 dividend stocks with yields > 3% offering attractive dividend yields and reliable payout histories.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NHI.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com